Therapy Areas: Vaccines
SGI-DNA Secures USD 25m series A Financing to Support Commercial Launch
10 September 2019 - - US-based SGI-DNA, a company focused on synthetic genomics technologies and revolutionary DNA data storage solutions, has completed a USD 25m series A financing round led by Northpond Ventures, with participation from Oxford Finance and BroadOak Capital Partners, the company said.

Proceeds of the financing will support the global commercial launch of the industry's first fully automated gene synthesis platform, further development of solutions that consolidate synthetic biology workflows, and the expansion of automated Gibson Assembly applications, including an instrument that converts digitized DNA code to biological entities and a novel suite of DNA data storage solutions.

In addition to the continuous commercial licensing of SGI-DNA's Gibson Assembly intellectual property estate, comprising over 50 issued patents, the company will accelerate the development of innovative solutions, including the DBC System (Digital-to-Biological Converter) for on-demand printing of biological materials such as therapeutics and vaccines, and proprietary approaches to DNA synthesis and DNA data storage.

Leveraging their Gibson Assembly Technology, SGI-DNA is well positioned to emerge as a leader in digital synthetic biology.

At SGI-DNA, our mission is to develop revolutionary synthetic genomics platforms that accelerate advances in drug discovery, precision medicine, DNA data storage and industrial design; bridging the gap between the digital and biological worlds.

Founded in 2014, SGI-DNA was officially spun out of Synthetic Genomics, Inc. in March of 2019.